NASDAQ: SNTISenti Biosciences Inc Stock
$3.88+0.04 (+1.04%)
Updated Apr 17, 2025
SNTI Price
$3.88
Fair Value Price
$3.21
Market Cap
$100.90M
52 Week Low
$1.52
52 Week High
$16.94
P/E
-0.32x
P/B
3.93x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$52.79M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.84
Operating Cash Flow
-$41M
Beta
1.27
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SNTI Overview
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SNTI's potential to beat the market
- SNTI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SNTI
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important SNTI news, forecast changes, insider trades & much more!
SNTI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SNTI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SNTI ($3.88) is overvalued by 20.99% relative to our estimate of its Fair Value price of $3.21 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SNTI ($3.88) is not significantly undervalued (20.99%) relative to our estimate of its Fair Value price of $3.21 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SNTI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SNTI due diligence checks available for Premium users.
Valuation
SNTI fair value
Fair Value of SNTI stock based on Discounted Cash Flow (DCF)
Price
$3.88
Fair Value
$3.21
Overvalued by
20.99%
SNTI ($3.88) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SNTI ($3.88) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SNTI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SNTI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.32x
Industry
-177.72x
Market
27.98x
SNTI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.93x
Industry
4.05x
SNTI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SNTI's financial health
Profit margin
Revenue
$0.0
Net Income
-$610.0k
Profit Margin
0%
SNTI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$97.8M
Liabilities
$47.1M
Debt to equity
1.84
SNTI's short-term assets ($58.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SNTI's short-term assets ($58.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SNTI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.5M
Investing
-$11.0k
Financing
$51.3M
SNTI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SNTI vs Biotech Stocks
Senti Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.